RE:RE:RE:The new chart & the 450 days duration % numbers.
Eoganacht wrote: The new format is fine, but it doesn't provide the durable complete response for the entire evaluated population of the trial and this is the first thing I look for when results come out.
Durable response is the secondary objective and it's an important way to compare our efficacy with already approved treatments. Keytruda finished with 19% and Adstiladrin with 24% On Nov 29 our 450 day CR rate for all treated patients was 28% What is it now?
I'm hoping in the future we continue to get data in both the new format and also the overall response rates.
Agree...a durable response means everything.
If you just look at our current 270+ day data, 11 of 27 (41%) have demonstrated a CR & 13 of 27 (48%) have shown an overall response (11 CR + 2 IR)...those are good numbers & they provide valuable insight as to durability.
If you also consider that block of patients at 180 days, 7 of 10 were CR at that point in time & 6 of 10 were able to maintain a CR at both 90 & 180 days. Based on current data trends, there's a good chance imo that 4 or 5 of those will maintain a CR moving forward. Extrapolating these numbers leads to 15-16 of 37 (41 to 43%) CR at 270+ days.
The above indicates to me (at least) that not only is this optimized treatment's high efficacy being maintained, so is its durability. I wouldn't be surprised to see a final 12 month durable response rate in the 30-40% range...all imo of course. Good luck...